Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients

What Was Tested

Researchers studied CJC-1295 (no DAC) (with/without DAC) + Ipamorelin and Ghrelin in this randomized controlled trial publication.

Ghrelin-receptor stimulation has promotility effects in the upper and lower gastrointestinal tract.

This proof of concept study was small and enrolled patients with a broad range of underlying conditions.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

The settings include hospital inpatients.

The patients were adults undergoing small and large bowel resection by open or laparoscopic surgery.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and multicenter study.

Because people in this CJC-1295 (no DAC) (with/without DAC) + Ipamorelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received CJC-1295 (no DAC) (with/without DAC) + Ipamorelin.

The comparison arm used a placebo, so changes seen with CJC-1295 (no DAC) (with/without DAC) + Ipamorelin could be set against what happens without it.

Running at several centres spread the CJC-1295 (no DAC) (with/without DAC) + Ipamorelin study over different clinics and patient groups.

The design was a multicenter, double-blind, placebo-controlled, clinical trial.

What Was Measured

Ghrelin-receptor stimulation has promotility effects in the upper and lower gastrointestinal tract.

The subject headings attached to it are Gastrointestinal Agents, Ileus, Intestines, Nausea, Oligopeptides, Postoperative Complications and Receptors, Ghrelin.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of CJC-1295 (no DAC) (with/without DAC) + Ipamorelin and Ghrelin.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2014 (International journal of colorectal disease), a journal based in Germany.

More context: the CJC-1295 (no DAC) (with/without DAC) + Ipamorelin compound page and the Ghrelin compound page, all human trials.